NCT04548583View on ClinicalTrials.gov

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Crohn Colitis
Interventions
DRUG

Remestemcel-L

adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis

DRUG

Remestemcel-L

adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis

OTHER

Placebo

Normal saline

Trial Locations (1)

44195

RECRUITING

Cleveland Clinic, Cleveland

Sponsors

Collaborators (1)

Mesoblast, Inc.
All Listed Sponsors
collaborator

Mesoblast, Inc.

INDUSTRY

lead

The Cleveland Clinic

OTHER